Advertisement

Hyperinsulinemia and VLDL Kinetics

  • George Steiner
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 334)

Abstract

The most frequent lipoprotein abnormality in diabetes mellitus is hypertriglyceridemia. The frequency of hypercholesterolemia is not very different from that found in the nondiabetic population.1,2 In those diabetic individuals who are grossly insulin deficient, the hypertriglyceridemia is due to an accumulation of chylomicrons, the primary transporters of dietary lipids. However, most diabetics, particularly those with NIDDM, do not have such severe insulin deficiency. In fact, as will be indicated below, many are hyperinsulinemic.3 In them the hypertriglyceridemia is due to an increased concentration of those triglyceride-rich lipoproteins that transport endogenous (i.e. nondietary) triglyceride. Such lipoproteins are generally called VLDL. However, they are in fact a population of lipoproteins that cover a wide spectrum of size and density. We have found, in nondiabetic individuals, that 75% of this population of lipoproteins is in the smaller, Sf 12–60 subpopulation of lipoproteins, a population also referred to as IDL.4 Based on kinetics considerations, this subpopulation in humans conforms to the characteristics of VLDL remnants.5 The remnant lipoproteins have been shown by many to be associated with an increased incidence of coronary artery disease.6–8

Keywords

Lipoprotein Lipase Plasma Free Fatty Acid Triglyceride Fatty Acid VLDL Secretion Insulin Treated Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zimmerman BR, Palumbo PJ, O’Falion WA, et al. A prospective study of peripheral arterila occlusive disease in diabetics, III. Initial lipid and lipoprotein findings. Mayo Clin Proc. 56:223 (1981).PubMedGoogle Scholar
  2. 2.
    Barrett-Connor E, Grundy SM, Holdbrook M.J. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol. 115: 657 (1982).PubMedGoogle Scholar
  3. 3.
    Steiner G. Insulin regulation of triglyceride metabolism. Atherosclerosis Revs. 22:2 (1991).Google Scholar
  4. 4.
    Poapst M, Reardon M, Steiner G. Relative contribution of triglyceride-rich lipoprotein particle size and number to plasma triglyceride concentration. Arteriosclerosis 5:381 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    Reardon MF, Steiner G. The use of kinetics in investigating metabolism of very low density and intermediate density lipoproteins in “Lipoprotein Kinetics and Modeling” Berman M, Grundy SM, Howard BV, eds. Academic Press, New York (1982).Google Scholar
  6. 6.
    Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation 75:124 (1987).PubMedCrossRefGoogle Scholar
  7. 7.
    Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 71:881 (1985).PubMedCrossRefGoogle Scholar
  8. 8.
    Krauss RM, Lindgren FT, Williams PT, et al. Intermediate density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet 11:62 (1987).CrossRefGoogle Scholar
  9. 9.
    Steiner G. Atherosclerosis, the major complication of diabetes, in “Comparison of Type I and Type II Diabetes.” Vranic M, Hollenberg CH, Steiner G, eds. Plenum Publishing Corp., Toronto, (1985).Google Scholar
  10. 10.
    Welborn TA, Wearn K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2:131 (1979).CrossRefGoogle Scholar
  11. 11.
    Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15 year follow-up. Diabetologia 34:356 (1991).PubMedCrossRefGoogle Scholar
  12. 12.
    Pyorala K, Savolainen E, Kaukola S, et al. Plasma insulin as a coronary heart disease risk factor: Relationship to other risk factors and predictive value during 9 year follow-up of the Helsinki Policeman Study population. Acta Med Scand. 701(Suppl):38 (1985).Google Scholar
  13. 13.
    Ronnemaa T, Laakso M, Pyorala K, et al. High fasting plasma insulin is an indicator of coronary heart disease in noninsulin-dependent diabetic patients and nondiabetic subjects. Arterioscl. and Thromb. 11:80 (1991).CrossRefGoogle Scholar
  14. 14.
    Ronnemaa T, Laakso M, Puukla P, et al. Atherosclerotic cardiovascular disease in middle aged insulin treated diabetic patients. Association with endogenous insulin secretion capacity. Arteriosclerosis. 8:23 (1988).Google Scholar
  15. 15.
    Nagi D, Hendra TJ, Ryle AJ, et al. The relationships of concentrations of insulin, intact proinsulin and 23–33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 33:532 (1990).PubMedCrossRefGoogle Scholar
  16. 16.
    Streja DA, Marliss EB, Steiner G. The effects of prolonged fasting on plasma triglyceride kinetics in man. Metabolism 26:505 (1977).PubMedCrossRefGoogle Scholar
  17. 17.
    Cattran DC, Steiner G, Wilson DR, Fenton SSA. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Int Med. 91:554 (1979).PubMedGoogle Scholar
  18. 18.
    Steiner G, Haynes FJ, Yoshino G, Vranic M. Hyperinsulinemia and in vivo very-low-density lipoprotein-triglyceride kinetics. Am J Physiol 246:E187 (1984).PubMedGoogle Scholar
  19. 19.
    Martin C, Desai KS, Steiner G. Receptor and post-receptor insulin resistance induced by in vivo hyperinsulinemia. Can J Physiol Pharmacol. 61:802 (1983).PubMedCrossRefGoogle Scholar
  20. 20.
    Brubaker LP, Kazumi T, Hirano T, Vranic M, Steiner G. Failure of chronic hyperinsulinemia to supress pancreatic glucagon in vivo in the rat. Can J Physiol Pharmacol. 69:437 (1991).PubMedCrossRefGoogle Scholar
  21. 21.
    Kazumi T, Vranic M, Bar-On H, Steiner G Portal v peripheral hyperinsulinemia and very low density lipoprotein triglyceride kinetics. Metabolism 35:1024 (1986).PubMedCrossRefGoogle Scholar
  22. 22.
    Durrington PN, Newton RS, Weinstein DB, Steinberg D. Effects of insulin and glucose on very-low-density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest. 70:63 (1982).PubMedCrossRefGoogle Scholar
  23. 23.
    Patsch W, Franz S, Schonfeld G. Role of insulin in lipoprotein secretion by cultured rat hepatocytes. J Clin Invest. 71:1161 (1983).PubMedCrossRefGoogle Scholar
  24. 24.
    Bartlett SM, Gibbons G.F. Short-and long-term regulation of very-low density lipoprotein secretion by insulin, dexamethasone and lipogenic substrates in cultured hepatocytes. A biphasic effect of insulin. Biochem J. 249:37 (1988).PubMedGoogle Scholar
  25. 25.
    Shumak SL, Zinman B, Zunig-Guarjardo S, Poapst M, Steiner G. Triglyceride-rich lipoprotein metabolism during acute hyperinsulinemia in hypertriglyceridemic humans. Metabolism. 37:461 (1988).PubMedCrossRefGoogle Scholar
  26. 26.
    Lewis GF, Uffelman KD, Szeto LW, Steiner G. Acute hyperinsulinemia decreases very low density lipoprotein (VLDL) triglyceride and VLDL apolipoprotein (Apo) B production in normal weight but not in obese men. Diabetes. in press (1993).Google Scholar
  27. 27.
    Ferguson K, Mamo J, Steiner G. (in preparation).Google Scholar
  28. 28.
    Raman M, Steiner G. Effect of insulin on VLDL-triglyceride secretion and glucose production in the perfused rat liver. Diabetes 39(suppl 1):45A(1990).Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • George Steiner
    • 1
  1. 1.Toronto General DivisionThe Toronto HospitalTorontoCanada

Personalised recommendations